TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of Participants With Any Serious Adverse Events (SAEs) up to 12 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Donor Lung Utilization Rate
Endpoint domain: Resource use
Primary endpoint: Prevalence of diabetes or glucose intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: net muscle protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved functional recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: microvascular flow index (MFI) of sublingual microcirculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events (AEs) Within 24 Hours Post Any Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With AEs Within 14 Days Post Any Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Discontinued From Study Due to AEs Occurring Within 24 Hours Post Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Discontinued From Study Due to AEs Occurring Within 14 Days Post Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Time to appropriate intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: high quality blastocyst formation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in dynamic compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Count of Participants With no More Than One Meter Glucose Value <50 mg/dL and no Values <40 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Count of Participants With no More Than Two Episodes With Meter Glucose Values Remaining >300 mg/dL for More Than 1 Hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Count of Participants With no Ketonemia, Seizures, or Loss of Consciousness
Endpoint domain: Adverse events/effects
Primary endpoint: Serum bactericidal activity responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of representation to Health Services for Exacerbation of URTI induced asthma
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Kupperman Menopausal Index (KMI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CTD incidence
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Achieving the Combined Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall number of patients with COVID-19 in ICU
Endpoint domain: Mortality/survival
Primary endpoint: Plasma Concentration-time Curves for ALA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Concentration-time Curves for PpIX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Complete Healing of Each Baseline DU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to Complete Healing of Each New DU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Change From Baseline in UK Systemic Sclerosis Functional Score (UKFS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PWV change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of ulcers healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iliac Vein Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Molecular changes in cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Angle of Trendelenburg during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Assessment Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Elimination of high-grade dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence, nature and severity of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of paracentesis procedures required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximal rate of force development (RFD) of isometric squat (MIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counter-movement jump (CMJ) rate of force development (RFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Squat jump height rate of force development (RFD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7 day point prevalence abstinence from smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of heart failure patients characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: All cause ICU and 28-day mortality
Endpoint domain: Mortality/survival
Primary endpoint: Organ dysfunction score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural and functional hepatic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life and psycho-social outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prognosis of procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact force variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to pulmonary vein isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of veins isolated after first pass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar reherniation at the index level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: need for dialysis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Occlusal Bite Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with oligosecretary myeloma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: depression symptom level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver stiffness changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VEGF Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With New Onset Chronic Medical Conditions (NOCMCs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal and fetal oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life as measured by SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain intensity as measured by NPSI-G
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain detection as measured by PAIN DETECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of C. difficile infection
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Sitting Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in UPDRS Parts II+III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC0-24) at Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Treatment Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proteomics changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved parent correct identification of child BMI category
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chronic musculoskeletal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Viscoelastic measurement Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality attributed to suicide or self-inflicted injury
Endpoint domain: Mortality/survival
Primary endpoint: Fugl-Meyer Motor Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to normalization of PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decreased admission rate to the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Healthcare provider assessment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: difference in body surface area (BSA) of non-sclerotic cutaneous cGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: dyspnea severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic/genomic knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trust in health care provider/researchers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Literacy/numeracy ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Average Concentration (Cave) of MK-8521 Corresponding to Slope of Insulin Secretion Rate/Glucose (ISR/G) During Graded Glucose Infusion (GGI) at Tmax After a Single Dose of MK-8521
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnosis or exclusion of cardiac amyloidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in the amount of streptococcus mutans and lactobacillus sp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Disability of Arm, Shoulder, and Hand (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: emotional memory function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of stimulated c-peptide at 90-minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: VAS pain score at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS pain score at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Without CRT-P Device Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: LV Pacing Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of doses received
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in overall fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Hepatic adherence severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loco-regional recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical measurements of pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical incidence of implants mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants that complete exercise program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants that complete nutrition program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of exercise sessions completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of days nutrition program followed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total HIV DNA From CD4 T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Major Coronary Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ODI Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: PROMIS-29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average Pain NRS (0-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst Pain NRS (0-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Nivolumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 27-hydroxylase level in THP-1 monocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracer Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body Height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body Mass Index (BMI) Percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety measured by (S)AE occurrences
Endpoint domain: Adverse events/effects
Primary endpoint: assessment of digestive sequelae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: assessment of global quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: assessment of quality of life - urinary sequelae
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Non-calcified Plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Device or procedure related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Who Achieved Hemoglobin (Hb) Stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Lactate Dehydrogenase (LDH) Concentration At Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain activation profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pap test adherence in women who smoke
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility, as measured by the percentage of eligible patients who can be enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in quality of life, as measured by questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in fatigue, as measured by questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Household air exchange rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of households that adopt the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Concentration of indoor particulate matter 2.5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal recto-vaginal GBS colonisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Neuropathic Pain Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: vaginal pallor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intravaginal potential of hydrogen (pH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytological examination of vaginal smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Female Sexual Function Index (FSFI) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Localization and management of tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: JOA recovery rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma lipoprotein profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metastasis-Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in perception of transition knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in attitudes about transition
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in participation in transition planning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean body weight (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Atrial Fibrillation or atrial flutter lasting at least 6 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Survival of suprastructures and implants
Endpoint domain: Mortality/survival
Primary endpoint: Composite Rate of All Death or All Myocardial Infarction (MI)
Endpoint domain: Mortality/survival
Primary endpoint: Change in bone mineral density at lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Acute heart failure events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ellipsoid zone area of IS/OS loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTC grade 3 and 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Average Pain Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of bladder perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Average blood glucose fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of moderately to highly damaging exonic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of levels of cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: maximum plasma concentration (Cmax) for Cebranopadol (GRT6005)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to maximum plasma concentration (tmax) for Cebranopadol (GRT6005)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration-time curve from 0 to time t (AUC0-t) for Cebranopadol (GRT6005)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nature, incidence, and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in myocardial perfusion reserve index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maintenance of normothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Global Acne Assessment Score (GAAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Functional Reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Lateral Reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stand Up Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in ambulatory systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma sodium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of paracentesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Amplitude of auditory steady state responses (ASSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spectro-temporal analysis of speech-ABR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitudes and latencies of P1/N1/P2 complex and Mismatch Negativity (MMN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of G3139
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT Thorax parameters reflecting emphysema and airway remodelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: C3 and AP Normalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of de Novo Hepatitis B Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline inspiratory force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent time of personal fitness tracker use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concentration of drug metabolites in cerebrospinal fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes